Haifang Du | Medicine and Health Sciences | Best Researcher Award

Published on by Forensic Scientist

Dr. Haifang Du | Medicine and Health Sciences | Best Researcher Award

The Second Affiliated Hospital of Guangzhou University of Chinese Medicine | China

Dr. Haifang Du is an Assistant Researcher at the Second Affiliated Hospital of Guangzhou University of Chinese Medicine and a researcher at the Guangdong Provincial Key Laboratory of Clinical Research on Traditional Chinese Medicine Syndrome, Guangzhou, China, specializing in targeted drug delivery, exosome technology, and natural product-based cancer therapy. She earned her Ph.D. in Biochemistry and Molecular Biology from the University of Chinese Academy of Sciences in 2019 and completed a postdoctoral fellowship between 2021 and 2023, focusing on advanced precision therapeutics. Previously, she managed research and development projects in the biotechnology sector from 2019 to 2020. Dr. Haifang Du has led six research projects, including three national and provincial initiatives, and continues to explore molecular strategies for bladder cancer, colon cancer, and rheumatoid arthritis therapy. Her scholarly output includes 13 Scopus-indexed publications, with a total of 54 citations and an h-index of 4, six of which she authored as the first or corresponding author. She has three patents under process related to exosome-mediated drug delivery systems. Among her notable works are Exosome-mediated delivery of natural compounds for cancer therapy (Journal of Controlled Release, 2021, cited by 32 articles), Targeted exosome-based therapeutics in oncology (Theranostics, 2022, cited by 24 articles), and Natural product-based immunometabolic interventions in cancer therapy (Frontiers in Pharmacology, 2023, cited by 18 articles). Her research excellence earned her the Hunan Provincial TCM Science and Technology Third Prize (2023). Through her continuous contributions to translational medicine, Dr. Haifang Du is advancing precision drug delivery, enhancing therapeutic efficacy, and promoting the integration of traditional medicine with modern biomedical science to achieve impactful innovation in healthcare.

Profile: Scopus

Featured Publications

  • Du, H., Yu, Y., Yan, X., & Zhang, P. (2025). Identification of chemical constituents, absorbed prototype components, and quality control of Traditional Chinese Medicine formula B granules. Journal of Pharmaceutical and Biomedical Analysis, 268, 117176. https://doi.org/10.1016/j.jpba.2025.117176

  • Huang, X., Wang, X., He, Z., Huang, Y., Hu, B., Chen, W., & Du, H. (2025). Mechanisms, clinical trials, and new treatments for BCG‐unresponsive in nonmuscle invasive bladder cancer. Cancer Medicine, 14(18). https://doi.org/10.1002/cam4.71243

  • Chen, Z., Guo, X., Wu, S., Wang, M., Wu, J., Du, H., Liang, H., Huang, R., & Huang, Q. (2025). Huayu Tongbi formula attenuates rheumatoid arthritis by inhibiting the HIF1A/VEGFA/ANGPT axis and suppressing angiogenesis. Phytomedicine, 139, 156479. https://doi.org/10.1016/j.phymed.2025.156479

Zhengfeng Jia | Medicine | Excellence in Research

Published on by Forensic Scientist

Prof. Dr. Zhengfeng Jia | Medicine | Excellence in Research

Fourth medical PLA general hospital | China

Dr. Zhengfeng Jia is a researcher in orthopedic biomechanics, focusing on distal humerus fractures, musculoskeletal dynamics, and finite element analysis. Affiliated with the Chinese PLA General Hospital and the National Clinical Research Center for Orthopedics, his work bridges computational modeling and clinical applications to optimize fracture fixation and rehabilitation strategies.

Professional profile👤

Scopus

Strengths for the Awards✨

  1. Innovative Methodology

    • The study integrates musculoskeletal dynamics (AnyBody software) with finite element analysis (Abaqus) to simulate real-world biomechanical conditions, overcoming the limitations of traditional static models.

    • The AnyBody-Abaqus coupling technique provides dynamic loading conditions, capturing muscle forces and joint reactions during elbow flexion/extension, which is rare in orthopedic biomechanics research.

  2. Clinical Relevance

    • Addresses a critical gap in distal humerus fracture management by quantifying “safe activity windows” for postoperative rehabilitation (e.g., ≤80° flexion for parallel plates, ≤30° for vertical plates).

    • Findings directly inform surgical decisions (e.g., plate configuration) and rehabilitation protocols to reduce complications like non-union.

  3. Rigorous Validation

    • Validates muscle forces using electromyography (EMG) literature and mesh convergence studies to ensure computational accuracy (<5% error).

    • Anatomical accuracy is confirmed via statistical shape modeling (SSM) and iterative closest point (ICP) algorithms (<1.2 mm error).

  4. High-Impact Results

    • Demonstrates that parallel plates outperform vertical plates in maintaining interfragmentary motion (IFM) within the healing threshold (0.06–0.20 mm).

    • Identifies stress migration paths in the humerus, correlating with anatomical weak zones (e.g., lateral condyle).

  5. Interdisciplinary Approach

    • Combines orthopedic surgery, biomechanics, and computational modeling, aligning with the trend of “smart orthopedics.”

Education 🎓

  • PhD Candidate in Orthopedics, Graduate School of Medical School of Chinese PLA Hospital, Beijing (Current).

  • Research training in musculoskeletal dynamics, 3D modeling, and finite element analysis (FEA).

Experience 💼

  • Researcher at the Fourth Medical Center of Chinese PLA General Hospital, Beijing.

  • Specializes in digital orthopedic technologies, including AnyBody-Abaqus joint modeling and biomechanical simulations.

  • Collaborates on studies quantifying “safe activity windows” for postoperative rehabilitation.

Research Interests On Medicine 🔍

  • Biomechanics of distal humerus fractures.

  • Musculoskeletal dynamics and finite element analysis (FEA).

  • Optimization of internal fixation plates and rehabilitation protocols.

  • AI applications in orthopedic decision-making.

Awards & Nominations 🏆

  • National Clinical Research Center for Orthopedics Grant (2024) for data-driven ulnar prostheses research.

  • Ethical approval recipient (2024KY005-KS001) for studies on fracture healing biomechanics.

Publications 📚

  1. Jia, Z., Xu, C., Gao, W., et al. (2025). Evaluation of internal fixation stability of distal humerus C-type fractures based on musculoskeletal dynamics: Finite element analysis under dynamic loading. Journal of Orthopaedic Surgery and Research, *20*(475).

  2. Contributed to meta-analyses on continuous passive motion post-arthroplasty (J Orthop Surg Res, 2024).

Conclusion 🌟

Zhengfeng Jia’s multidisciplinary research quantifies biomechanical thresholds for fracture healing, emphasizing parallel plate configurations and 30–80° flexion safety windows. His integration of AnyBody-Abaqus modeling advances personalized rehabilitation strategies, with future aims to validate findings in clinical trials and AI-driven orthopedic solutions.

Xiaoling Ma | Medicine | Best Researcher Award

Published on by Forensic Scientist

Prof. Xiaoling Ma | Medicine | Best Researcher Award

Chief physician | The first hospital of Lanzhou university | China

Dr. Xiaoling Ma is a distinguished Chief Physician and Associate Professor, currently serving as the Director of the Reproductive Medicine Center at The First Hospital of Lanzhou University. With over two decades of experience in reproductive medicine, she has made significant contributions to the advancement of assisted reproductive technology (ART). Dr. Ma is a nationally recognized expert in ART management and holds key positions in several prestigious reproductive medicine organizations in China. Her expertise encompasses reproductive endocrinology, fertility preservation, and genetic screening technologies.

Profile👤

Scopus

Strengths for the Awards✨

✅ Extensive Research Contributions: Xiaoling Ma has published over 30 articles in SCI and core Chinese journals, indicating a strong research output. Recent publications in Biomedicine & Pharmacotherapy, Reproductive Sciences, and BMC Medical Genomics highlight her contributions to reproductive medicine.

✅ Leading Research and Innovation: She has led multiple national and provincial research projects, including studies on reproductive genetics, fertility preservation, and endometriosis mechanisms.

✅ Academic and Professional Influence: As a chief physician, associate professor, and director of the Reproductive Medicine Center, her influence extends to clinical practice, academic mentorship, and policy advisory roles.

✅ Editorial and Professional Leadership: Serving as the Chinese editor for Human Reproduction Update and holding key roles in reproductive medicine associations in China demonstrate her leadership in the field.

🎓 Education

Dr. Xiaoling Ma obtained her Master’s degree in Medicine from a renowned Chinese institution. She has pursued extensive postgraduate training and specialized programs in reproductive medicine, refining her knowledge in assisted reproductive technology, reproductive endocrinology, and genetic screening. Her continuous pursuit of academic excellence has positioned her as a leading educator and mentor in reproductive healthcare.

💼 Experience

With a distinguished career spanning over 20 years, Dr. Ma has been instrumental in pioneering and implementing ART techniques. She has successfully led numerous national and provincial medical projects in China, focusing on fertility evaluation, genetic screening, and reproductive health. In addition to her clinical practice, she plays a pivotal role in policy-making and regulatory aspects of reproductive medicine, ensuring the ethical implementation of ART procedures. As an educator, she has trained and mentored countless physicians, enhancing the field of reproductive medicine across China.

🔬 Research Interests On Medicine

Dr. Ma’s research is dedicated to three-level prevention and control of birth defects, fertility preservation in cancer patients, and the application of genetic screening in reproductive health. She explores the mechanisms behind endometriosis, recurrent pregnancy loss, and infertility, aiming to develop innovative treatment protocols. Her contributions to preimplantation genetic testing (PGT) and reproductive immunology have significantly influenced reproductive healthcare in China and beyond.

🏆 Awards and Recognitions

Dr. Ma has been recognized for her outstanding contributions to reproductive medicine and has received multiple accolades at the national and provincial levels. She is an esteemed member of leading reproductive medicine societies and has played a crucial role in shaping policies related to ART in China. She has also been actively involved in national academic conferences, furthering research and clinical advancements in reproductive health.

📚 Publications

Dr. Ma has published over 30 research articles in SCI-indexed and Chinese core journals. Below are some of her notable publications:

  1. Guan, D., Sun, W., Gao, M., Chen, Z., & Ma, X. (2024). Immunologic insights in recurrent spontaneous abortion: Molecular mechanisms and therapeutic interventions. Biomedicine & Pharmacotherapy, 177, p.117082. [Cited by articles]
  2. Liu, L., Liu, Y., Tian, Y., Cao, Y., Wang, T., Mi, S., Yang, R., Liu, S., Ma, X., & Wang, J. (2024). Identification of differentially expressed mRNAs and lncRNAs contributes to elucidation of underlying pathogenesis and therapeutic strategy of recurrent implantation failure. Reproductive Sciences, pp.1-14. [Cited by articles]
  3. Wang, T., Zhang, L., Gao, W., Liu, Y., Yue, F., Ma, X., & Liu, L. (2024). Transcriptome-wide N6-methyladenosine modification profiling of long non-coding RNAs in patients with recurrent implantation failure. BMC Medical Genomics, 17(1), p.251. [Cited by articles]
  4. Guan, D., Zhao, L., Shi, X., Ma, X., & Chen, Z. (2023). Copper in cancer: from pathogenesis to therapy. Biomedicine & Pharmacotherapy, 163, p.114791. [Cited by articles]

🔚 Conclusion

Dr. Xiaoling Ma is a pioneering figure in reproductive medicine, dedicated to advancing ART and genetic screening technologies. Her extensive clinical expertise, innovative research, and leadership in reproductive medicine make her a highly respected figure in her field. Through her work, she continues to impact countless lives, improving fertility treatments and reproductive healthcare policies. Her commitment to teaching, research, and patient care ensures a lasting legacy in reproductive medicine.